Eutilex Submits Clinical Trial Application for Immuno-Oncology Drug EU101 Phase 1/2 Study
[Asia Economy Reporter Oh Ju-yeon] Eutilex announced on the 21st that it has submitted a clinical trial application for Phase 1/2 of the immuno-oncology drug EU101 to the U.S. Food and Drug Administration (FDA). The company explained, "EU101 activates and proliferates killer T cells of the immune system that attack cancer in patients with advanced solid tumors, and is expected to minimize treatment side effects, reduce and control tumor size, extend progression-free survival, extend overall survival, and improve quality of life."
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
